GlassScriptPhysician profile
Justin Shippen
NPI 1871941724
$1,225.41
in general payments reported to CMS, 2019-2025
29 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.38 · 2020: $49.76 · 2021: $85.83 · 2022: $212 · 2023: $148 · 2024: $429 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $152.74 | 2021-2024 | |
| Astellas Pharma US INC | $129.29 | 2019-2024 | Veozah |
| Axsome Therapeutics, INC. | $126.23 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $82.49 | 2024-2025 | Fanapt |
| Stryker Corporation | $80.42 | 2024 | Infinity Adaptis |
| Janssen Pharmaceuticals, INC | $73.80 | 2021-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $56.48 | 2019-2023 | Rexulti |
| Daiichi Sankyo INC. | $52.48 | 2024-2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $36.48 | 2023-2024 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $36.04 | 2019-2022 | |
| Novo Nordisk INC | $34.96 | 2024-2025 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $31.91 | 2024-2025 | Voquezna |
| Insulet Corporation | $27.93 | 2025 | Omnipod |
| Exact Sciences Corporation | $27.06 | 2025 | The Cologuard Plus Collection Kit |
| Neuronetics, INC. | $27.03 | 2025 | Neurostar Tms Therapy System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.63 | 2019 | |
| Pfizer INC. | $22.19 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.87 | 2022 | |
| Mylan Specialty L.P. | $20.72 | 2024 | Yupelri |
| Biogen, INC. | $19.36 | 2022 | |
| Amarin Pharma, INC. | $18.91 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.62 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $16.91 | 2022 | |
| Allergan, INC. | $16.74 | 2020 | |
| Corium, LLC | $16.55 | 2023 | Azstarys |
| Tris Pharma INC | $16.01 | 2023 | Dyanavel Xr |
| Lilly USA, LLC | $14.20 | 2023 | Mounjaro |
| Biohaven Pharmaceuticals, INC. | $12.37 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Shippen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.